An Open-Label Extension to Evaluate the Safety and Efficacy of Pregabalin for Treatment of Chronic Central Neuropathic Pain After Spinal Cord Injury.

Trial Profile

An Open-Label Extension to Evaluate the Safety and Efficacy of Pregabalin for Treatment of Chronic Central Neuropathic Pain After Spinal Cord Injury.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2014

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Central pain; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 03 May 2014 Results from a pooled analysis presented at the 33rd Annual Scientific Meeting of the American Pain Society.
    • 03 May 2014 Sleep interference results from a pooled analysis presented at the 33rd Annual Scientific Meeting of the American Pain Society.
    • 03 May 2014 Results presented at the 33rd Annual Scientific Meeting of the American Pain Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top